Newsbenzinga
Monte Rosa Therapeutics To Present Phase 1 Data For MRT-8102 In People With Elevated Cardiovascular Risk On October 1
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…